ClinicalTrials.gg
RecruitingNCT07563270GAPcareADUpdated Nov 9, 2026

GAPcareAD: A Brief Emergency Department Intervention to Address Post-Fall Care Needs of Persons Living With Dementia and Care Partners

An interventional study of Fall Prevention in Alzheimer's Disease and Related Dementia, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 9, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Alzheimer Disease by University of Colorado, Denver — 4 open to participants now, 5 under way, none of them phase 3. Alzheimer Disease · University of Colorado, Denver.

Started
2026
the only one that year
No phase
6 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Alzheimer Disease by University of Colorado, Denver, this one is the only one that started in 2026, is one of 6 with no phase, and was the 12th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 12 studies in Alzheimer Disease by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alzheimer Disease by University of Colorado, Denver, or all of them as a file.
02

Study summary

Persons living with dementia (PLWD) are at significantly increased risk for falls, which are the leading cause of emergency department (ED) visits in this population and contribute to serious injuries, functional decline, and caregiver burden. GAPcareAD is an ED-initiated, caregiver-inclusive intervention designed to address fall risk at the point of care. This multi-site trial will compare GAPcareAD (intervention) to usual care for 350 PLWD and caregivers after a fall.

Read the detailed description

This multi-site randomized controlled trial will evaluate the efficacy of GAPcareAD compared to usual care among 350 PLWD and their caregivers (dyads) presenting to one of the three EDs after a fall. The intervention includes pharmacist- and physical therapist-led assessments, targeted modification of fall risk factors, and coordinated communication of fall prevention plans with caregivers and care teams. Outcomes include fall-related ED visits, injuries, hospitalizations, quality of life, caregiver burden, and adherence to recommendations over 6 months. GAPcareAD aims to determine whether a pragmatic, ED-based intervention can reduce fall-related healthcare utilization and improve patient and caregiver outcomes, while informing future large-scale implementation.

03

Conditions studied

  • Alzheimer's Disease and Related Dementia

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Community-dwelling adult (living at home or assisted living) 65 years-old or older presenting to ED after a fall within the last seven days
  • Fall not due to syncope or external force (i.e., struck by car,assault, intoxication)
  • Fall not due to serious illness (i.e., stroke, acute myocardial infarction)
  • Patients have an identified caregiver
  • Patient must have known ADRD or score ≥2 on the AD8 Dementia Interview.
  • Anticipated to be discharged to home/assisted living/rehabilitation at the time of consent (i.e. not admitted)
  • The patient and/or caregiver have a reliable phone number where they can be reached throughout the intervention

Exclusion criteria

Exclusion Criteria:

  • Living in a nursing home
  • Patients are admitted to the hospital
  • Patients who have advanced cancer and/or are in hospice
  • Patients have presence of injuries that prevent mobilization (i.e. pelvic or lower extremity fractures)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Intervention

    GAPcareAD - See intervention description.

    Other: Fall Prevention

  • No intervention
    Usual Care

    The ED clinician will perform a standard medical evaluation and care.

Interventions

  • OtherFall Prevention

    GAPcareAD - Pharmacists perform medication review and recommend modifying fall risk increasing medication. PTs perform fall risk assessments and tailor recommendations based on fall risk and patient's gait, balance, and mobility impairments. Through purposeful engagement by staff, caregivers are encouraged to contribute to the action plans.

06

What researchers measure

Primary outcomes

  1. Effect of intervention

    The primary outcome is the number of fall-related emergency department visits per participant within 6 months after randomization, comparing participants receiving the GAPcareAD intervention verses usual care.

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
  • UCH University of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
    • Jamie Mills, CCRC, MS · Contactjamiem@wustl.edu · 314-747-4510
    • Stacey House, MD, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 29 months is close to that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
May 4, 2026
StartActual
Oct 13, 2026was Sep 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 31, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • UCH University of Colorado · Aurora, United States
  • Washington University · St Louis, United States
Nov 9, 2026
Start date
Sep 30, 2026→Oct 13, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • UCH University of Colorado · Aurora, United States
    • Washington University · St Louis, United States
    Start date Sep 30, 2026→Oct 13, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07563270
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Oct 13, 2026
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion